To help clinical labs performing NGS-based myeloid testing characterize the limit of detection (LOD) of their liquid biopsy assays and validate robust sensitivity, SeraCare has developed myeloid cancer NGS reference material in ctDNA format to ensure compatibility with existing and emerging myeloid assays.
Single sample with 25 clinically relevant DNA variants across 17 genes
Expert-designed to ensure coverage across important variants (mix of SNVs, INDELs, and ITD) at relevant allele frequencies (1%, 0.5%, 0.1%, WT)
Built with innovative technology to produce patient-like sample performance in NGS assays
Variants precisely quantified using highly sensitive digital PCR assays, and blended with a single well-characterized genomic background (GM24385)
Validated by targeted NGS panels
Manufactured in GMP-compliant, ISO 13485-certified facilities